


CHDR  
Centre for Human Drug Research

# Disclosure

- Study co-funded by Cutanea Life Sciences
- No other conflict of interests to declare



# Comprehensive, multi-modal characterization of an imiquimod-induced human skin inflammation model


Tessa van der Kolk, MD

Centre for Human Drug Research, Leiden, The Netherlands

# Introduction

- Imiquimod; TLR 7/8 agonist
- Local skin inflammation through MyD88 signaling pathway
- Psoriasis exacerbations after treatment
- Development mouse model
- No short human model for drug development

# Role of TLR 7 in Autoimmune Disease Cycle





**Dendritic and B Cell Express TLRs 7**  
*Immune complexes activate TLRs 7, 8, and 9, present on dendritic cells and B cells and induce pro-inflammatory cytokines*

# Objectives

- To develop an acute skin inflammation challenge model with;
  - 1) topical IMQ application for 24, 48 and 72 hours on a fully competent skin barrier
  - 2) topical IMQ application for 24, 48 and 72 hours on tape stripped skin

# Study design

- Open label
- Vehicle controlled
- Dose-ranging
- Parallel cohort with tape stripping
- Healthy volunteers (18-45yoa)




# Pharmacodynamic endpoints

- Clinical (physician erythema scoring)
- Imaging (colorimetry and erythema index)
- Biophysical (perfusion by Laser Speckle Contrast Imaging)
- Molecular (mRNA expression)
- Cellular (histology and immunohistochemistry)




# Clinical impression




# CLINICAL


## Visual grading





# IMAGING







# BIOPHYSICAL




# MOLECULAR




# Histology impression




# CELLULAR



- 3 fold
- 2.5 fold
- 2 fold
- 1.5 fold
- Reference
- 0.5 fold
- Absent




# Multimodal characterization





# Multimodal characterization




# Conclusion

- Successful development of a fully characterized, acute IMQ-induced skin inflammation model
- Well-tolerated (no discontinuations, not shown)
- Clinical and histological phenotype fully concordant in TS+IMQ cohort
- TS of the skin needed for quicker inflammatory response
- 48h application most optimal for the model
- Future: *proof of pharmacology* and *drug profiling* of novel compounds targeting the innate immune system

# Acknowledgements

- Salma Assil
- Rianne Rijnveld
- Erica Klaassen
- Gary Feiss
- Eddy Florencia
- Errol Prens
- Martijn van Doorn
- Koos Burggraaf
- Matthijs Moerland
- Robert Rissmann



# CHDR

Centre for Human Drug Research